Abstract

SARS-CoV-2 had a pertinent implication on people’s daily lives and medical procedures during the pandemic or even after it. COVID-19 infections varied in the clinical aspect from mortality to asymptomatic episodes. The symptoms included fever, cough, difficulty breathing, loss of mobility, and chest pain. On the other hand, the patients who passed away from COVID-19 showed multiple organ failure, respiratory dysfunction, and disseminated coagulations throughout the body. D-dimer is a biomarker implemented in blood clotting and is commonly elevated in patients with thrombotic complications. This review sheds light on the correlation between gene mutations in the coagulopathy cascade among COVID-19 patients with high D-dimer levels. The elevated D-dimer levels are significantly associated with mutations in genes involved in the coagulopathy cascade. The findings suggest that these mutations may play an important role in developing thrombotic problems in COVID-19 patients. As a result, understanding the genetic basis of thrombotic development in COVID-19 could lead to new ways of avoiding and treating thrombotic problems.

Key words: COVID-19; Hematology; Coagulation; D-Dimer; Fibrinogen;‎‏ ‏Immunothrombosis